Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine

Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine

In the last decade, notable progresses have been observed in chronic migraine preventive treatments. According to the European Headache Federation and national provisions, onabotulinumtoxin-A (BTX-A) and monoclonal antibodies acting on the pathway of calcitonin gene–related peptide (CGRP-mAbs) shoul...

Full description

Bibliographic Details
Main Authors: Marcello Silvestro, Alessandro Tessitore, Fabrizio Scotto di Clemente, Giorgia Battista, Gioacchino Tedeschi, Antonio Russo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Neurology
Subjects:
monoclonal antibodies
erenumab
onabotulinumtoxin-A
refractory migraine
migraine
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.656294/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2021.656294/full

Similar Items